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Motor neuron diseases (MNDs) are characterized by selective death of motor neurons
and include mainly adult-onset amyotrophic lateral sclerosis (ALS) and spinal muscular
atrophy (SMA). Neurodegeneration is not the single pathogenic event occurring during
disease progression. There are multiple lines of evidence for the existence of defects in
lipid metabolism at peripheral level. For instance, hypermetabolism is well characterized in
ALS, and dyslipidemia correlates with better prognosis in patients. Lipid metabolism plays
also a role in other MNDs. In SMA, misuse of lipids as energetic nutrients is described in
patients and in related animal models. The composition of structural lipids in the central
nervous system is modified, with repercussion on membrane fluidity and on cell signaling
mediated by bioactive lipids. Here, we review the main epidemiologic and mechanistic
findings that link alterations of lipid metabolism and motor neuron degeneration, and
we discuss the rationale of targeting these modifications for therapeutic management
of MNDs.
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INTRODUCTION
Motor neuron diseases (MNDs) are a group of incurable neuro-
logical disorders caused by the selective degeneration of motor
neurons. Amyotrophic lateral sclerosis (ALS) is the most repre-
sentative MNDs among adults with a incidence rate of 2–3 per
100,000 (Brooks et al., 2000). It is characterized by progressive
muscle weakness and atrophy, loss of upper and lower motor
neurons and death ensuing 3–5 years after diagnosis. Majority of
ALS patients are of sporadic origin with unclear ethiopathology.
Several mutations are associated with ALS, in particular in genes
encoding superoxide dismutase 1 (SOD-1), TAR DNA binding
protein of 43-kDa (TDP-43), fused in sarcoma (FUS) and chro-
mosome 9 open reading frame 72 (C9ORF72) (Rosen et al., 1993;
Mackenzie et al., 2007; Deng et al., 2010; Laaksovirta et al., 2010;
Shatunov et al., 2010). Thus, several transgenic mouse models
overexpressing various mutant genes have been developed, and
the SOD1 model, overexpressing a mutated form of SOD1 gene,
is the most studied in ALS (Ripps et al., 1995). Spinal muscular
atrophy (SMA) is a genetic autosomal and recessive neuromus-
cular disease, caused by loss of functional survival motor neuron
(SMN) gene 1. Patients suffer from degeneration of spinal motor
neurons, muscle weakness leading to atrophy. Disease severity
ranges from severe, with death of patients before the age of
10, to mild with moderate symptoms with no alteration of life
expectancy. Spinal bulbar muscular atrophy (SBMA), also known
as Kennedy’s disease, is an X-linked recessive disease caused by a
CAG-repeat expansion in the gene coding for the androgen recep-
tor, leading to a poly-Q repeat expansion in the protein (Brooks
and Fischbeck, 1995; Fischbeck et al., 1999). The disease affects
mainly males, even though it has been described also in female
patients. SBMA is characterized by progressive muscle atrophy
and degeneration of lower motor neurons in the brain stem and
spinal cord. Similarly to ALS, mouse models have been developed
to study SMA and SBMA (Katsuno et al., 2003; Bebee et al., 2012).
Along with neuronal degeneration, several alterations of lipid
metabolism are found in these diseases. Here, we review the role
of lipids in MNDs, with a special attention on energy homeosta-
sis, cell signaling and structure. We further discuss the rationale
of targeting lipid metabolism for therapeutic management of
MNDs.
ENERGETIC ALTERATIONS IN AMYOTROPHIC LATERAL
SCLEROSIS
Multiple previously unrecognized phenotypes occur in ALS
patients, in particular, the unbalance between food intake and
energy (Braun et al., 2012; Muscaritoli et al., 2012). ALS
patients often present with dyslipidemia, reduced body mass and
increased resting energy expenditure (Table 1, Desport et al.,
2001; Funalot et al., 2009; Dupuis et al., 2011). Energetic alter-
ations are similarly found in transgenic animal models of ALS,
the SOD1 mice. These mice are leaner than controls, hyperme-
tabolic, hypolipidemic and present increased fatty acid uptake in
muscles (Table 2, Dupuis et al., 2004; Fergani et al., 2007; Kim
et al., 2011). Several lines of evidence point to lipid metabolism
alterations being crucial for ALS progression. A first incidental
event shed some light on the subject. During 2 years, a group
of scientists remain in an isolated environment, and were sub-
mitted to long term caloric restriction (Walford et al., 2002).
From eight members of the group, one died from ALS and
another one developed progressive gait impairment and motor
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Table 1 | Altered energetic metabolism in ALS patients.
Items Cohort size (ALS patients) Outcomes References
BASAL METABOLISM IN ALS
N = 62 ALS patients are hypermetabolic. Desport et al., 2001
N = 44 ALS patients are hypermetabolic. Funalot et al., 2009
EPIDEMIOLOGIC AND RISKS TO ALS
N = 153 High carbohydrates and low fat intakes increase ALS risk. Okamoto et al., 2007
N = 222 High prediagnostic body fat is associated with a decreased risk of ALS mortality. Gallo et al., 2013
LIPIDS AND PROGNOSIS IN ALS
N = 369 High LDL/HDL ratio correlates to longer survival. Dupuis et al., 2008
N = 658 Hyperlipidemia does not correlate to longer survival. Chio et al., 2009
N = 658 Low level LDL/HDL ratio correlates to respiratory dysfunction. Chio et al., 2009
N = 285 Low BMI correlates to faster decline. Jawaid et al., 2010
N = 92 Poor nutritional status is associated with higher mortality. Marin et al., 2011
N = 488 High triglycerides or cholesterol correlates to longer survival. Dorst et al., 2011
N = 427 High BMI correlates to longer survival. Paganoni et al., 2011
N = 77 Fast reduction of BMI predicts faster decline. Shimizu et al., 2012
N = 150 High BMI correlate to slower ALSFRS score decline. Reich-Slotky et al., 2013
N = 62 High subcutaneous fat positively correlate to survival. Lindauer et al., 2013
Table 2 | Altered energetic metabolism in mouse models of MNDs.
Model Cohort size Conclusion References
ALS
SOD1 G93A mice N = 8 Altered composition of lipids in spinal cord. Cutler et al., 2002
SOD1 G86Rand G93A mice N = 7–8 Dramatic defect in energy homeostasis, hypermetabolism mainly of
muscular origin.
Dupuis et al., 2004
N = 13 High fat diet delays disease onset and extent survival. Dupuis et al., 2004
SOD G93A mice N = 27 The ketogenic diet protects against motor neuron death. Zhao et al., 2006
SOD1 G86Rand G93A mice N = 10–15 Hypolipidemia is found in SOD1 mice. Fergani et al., 2007
SOD1 G93A mice N = 49 females
N = 31 males
Caloric restriction shortens lifespan through an increase in lipid peroxidation,
inflammation and apoptosis.
Patel et al., 2010
SOD1 G93A mice N = 30 males Hypolipidemia is present at the presymptomatic stage of disease. Kim et al., 2011
SOD1 G93A mice N = males Medium chain triglycerides protect motoneurons survival but does not
extent survival.
Zhao et al., 2012
SMA
SMN1 deficient mice N = 30 males Hypolipidemia is present at the pre-symptomatic stage of disease. Butchbach et al., 2010
neuron degeneration. Epidemiological studies went beyond this
case study and documented an association between nutrition and
the risk of developing ALS. First, a case control survey made in
Japan in 2007 was conducted with the aim to study pre-illness
nutritional habits of ALS patients. The authors identified that
high carbohydrate and low fat intakes are associated with higher
ALS risk (Table 1, Okamoto et al., 2007). More recently, another
epidemiologic study focused on anthropometric characteristics of
the general population with a follow up over 10 years. The inves-
tigators reached the conclusion that high fat content reduces the
risk of developing ALS (Gallo et al., 2013). These clinical data are
consistent with the reduced overall survival of SOD1 mice under
caloric restriction (Table 2) (Hamadeh et al., 2005).
Conversely, increased energy intake is beneficial for SOD1
mice. The first evidence emerged in 2004 from our laboratory,
when we fed SOD1 mice with a diet enriched in lipids. The
treatment restored normal body mass and adiposity, delayed dis-
ease onset and motor neuron degeneration, and life expectancy
was extended by 20% (Dupuis et al., 2004). The beneficial effects
of high fat diet, or ketogenic diet, for SOD1 mice were con-
firmed by other groups (Table 2, Mattson et al., 2007; Zhao et al.,
2006, 2012). In 2008, we aimed to study the link between lipids
and disease progression, by quantifying circulating lipids in ALS
patients. We found that dyslipidemia, defined by high LDL/HDL
ratio, was a characteristic of the ALS group (Dupuis et al., 2008),
and this dyslipidemia positively correlated with longer survival,
increased by 13 months in the group of ALS patients with higher
LDL/HDL ratio. Since then, others reported that either hyper-
lipidemia or high body mass index is a strong prognostic factor
for survival (Dorst et al., 2011; Paganoni et al., 2011; Shimizu
et al., 2012; Reich-Slotky et al., 2013). For instance, the median
life expectancy was higher than 14 months in patients with high
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serum triglyceride levels (Dorst et al., 2011). Last, it was recently
observed that subcutaneous fat positively correlated with sur-
vival of ALS patients (Lindauer et al., 2013). Conversely, lower
LDL/HDL ratio has been linked to respiratory impairments (Chio
et al., 2009), fast loss of BMI was associated with faster decline
(Jawaid et al., 2010) and poor nutritional status is a negative
prognosis factor (Marin et al., 2011).
These reports claim for a positive correlation between high cir-
culating lipid levels of lipids or high fat mass and prognosis of
ALS patients. The mechanisms in place deserve further investiga-
tion, to understand how peripheral lipids interfere with disease
progression and how lipids can preserve motor axis integrity.
ENERGETIC SUBSTRATES AND MOTOR UNITS
Themotor unit is an anatomical structure responsible for the con-
trol of muscle contraction and its destruction represents the first
detectable event in ALS (Dupuis and Loeffler, 2009). The motor
units are composed of different sorts of spinal motor neurons and
muscles fibers, depending on their activity and energetic capaci-
ties. Fast fatigable motor units are composed of large alpha-motor
neurons and glycolytic muscle fibers that burn preferentially glu-
cose to exert heavy force on a short period. Conversely, slow
motor units correspond to small alpha-motor neurons and oxida-
tive muscle fibers, which store and use preferentially fatty acids
to produce less intense but constant strength. Large alpha motor
neurons are the first to degenerate in ALS models (Pun et al.,
2006; Hegedus et al., 2007), and fast-twitch motor units are
preferentially affected in both ALS patients and mouse models
(Schmied et al., 1999; Atkin et al., 2005; Gordon et al., 2010).
Stimulation of motor units via regular training was proposed
to maintain and strengthen motor function in ALS (Table 3).
Clinical investigations reported benefit for ALS patients whom
followed moderate and mainly aerobic exercise program, which
use lipids as energy source (de Almeida et al., 2012). In particular,
specific training of the diaphragma preserved respiratory func-
tions in ALS patients (Mahajan et al., 2012). It should be noted
that these studies were not randomized and suffer from the small
size of the cohorts. Moreover, higher release of reactive oxygen
species during exercise was reported (Siciliano et al., 2002) and
suggest that design for muscular training in ALS patients should
be considered with caution (Table 3).
In an animal model of ALS, effects of high frequency and high
amplitude training were compared to moderate and endurance
training. SOD1 mice were subjected either to swimming-based
training, targeting glycolytic motor units, or to running-based
training, targeting oxidative motor units (Deforges et al., 2009).
After training, the group of “swimmer” mice presented with ben-
efits in terms of counts of motor neurons and survival, when
compared to proper control. On the contrary, the “running”-
trained mice presented a similar disease course compared to
sedentary mice. Effect of training on SOD1 mice is not fully
clarified. Others reported claimed that moderate exercise alone
can improve outcomes in SOD1 mice (Carreras et al., 2010),
and most importantly, Gerber and colleagues recently demon-
strated that benefits of training in mice might come from
the enrichment of the environment rather than mobilization
of muscle fibers (Gerber et al., 2012). Therefore, the benefit
after different types of training for SOD1 mice targeting dif-
ferent pool of motor units remains to be clarified. Currently,
the effects of aerobic versus anaerobic exercises on vital capac-
ity and muscular strength are under clinical investigations
(Table 4, NCT01650818, NCT01521728). Additional work on
this topic is required to understand the impact of different
exercises, using different energetic sources, on motor units in
ALS patients, and why glycolytic motor units are preferentially
affected.
ENERGY, METABOLISM, AND MITOCHONDRIA
Taken separately, the two extremities of the motor units, the mus-
cles and the motor neurons, show abnormal lipid metabolism.
Indeed, early in the disease course, glycolytic muscles of SOD1
mice switch toward an oxidative phenotype, presumably due to
the loss of their connection to large motor neurons and subse-
quent reinnervation by “slow”motor neurons (Sharp et al., 2005).
The selective vulnerability of large motor neurons is potentially
due to higher energetic needs that could either be not fulfilled
or a source of oxidative stress. In case of higher needs, neu-
rons can use ketone bodies as energetic substrate when glucose
level becomes low (Guzman and Blazquez, 2004; LaManna et al.,
2009). In this situation, astrocytes will use lipid to provide ketone
bodies to neurons, and potentially motorneurons in ALS (Yi et al.,
2011). Interestingly, medium chain triglycerides, precursors of
ketone bodies, preserve motor functions and promote motorneu-
ron survival in SOD1 mice through the enhancement of oxidative
metabolism (Table 2, Zhao et al., 2012).
Moreover two recent studies have shown abnormally enhanced
levels of ketone bodies, released by the breakdown of fatty acids, in
the cerebrospinal fluid of ALS patients (Blasco et al., 2010; Kumar
Table 3 | Effect of exercise in ALS.
Cohort Outcomes References
SOD1 MICE G93A
High frequency and amplitude training support in motor neuron survival. Deforges et al., 2009
Moderate frequency and amplitude training support motor neurons survival. Carreras et al., 2010
Benefits of training might come from the enrichment of the environment. Gerber et al., 2012
ALS PATIENTS
Regular moderate physical exercise should be recommended. Drory et al., 2001
Higher release of ROS during exercise suggests that design of training should be considered with caution. Siciliano et al., 2002
Benefits of moderate aerobic exercise. Bello-Haas et al., 2007
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Table 4 | Ongoing clinical trials in ALS.
Items Clinical trial ID Status Study type Intervention Estimated Study
enrollment
EXERCISE
NCT01650818 Recruiting Interventional Endurance training 40 Aerobic exercise training in ALS
NCT01521728 Recruiting Interventional Resistance exercise 60 Trial of resistance and endurance exercise in ALS
DIETARY SUPPLEMENT
NCT00983983 Completed Interventional Oxepa 30 High fat/high calorie trial in ALS
NCT01016522 Terminated Interventional KetoCal NA Safety and tolerability of the ketogenic diet in ALS
BASAL METABOLISM
NCT00714220 Recruiting Observational / 150 Quantitative measurement of nutritional
substrate utilization in patients with ALS
NCT01592084 Completed Observational / 267 Hyperlipidemia and statin therapy in ALS
PHARMACOLOGY
NCT00690118 Terminated Interventional Pioglitazone (45mg/day) 219 Study of pioglitazone in patients with
Amyotrophic Lateral Sclerosis
NCT00876772 Unknown Interventional Olanzapine (10mg/day) 40 Olanzapine for the treatment of appetite loss in
Amyotrophic Lateral Sclerosis (ALS)
Clinical trial IDs refer to the current nomenclature used at clinicaltrial.gov.
et al., 2010) that could account for an altered lipid beta oxidation
in the CNS of ALS patients.
Higher energetic needs have been documented in muscle of
SOD1 mice (Dupuis et al., 2004). In the animal model, the
metabolic shift in muscle fibers (glycolytic to oxidative) could
explain the pronounced appetence for fatty acids in SOD1 mus-
cles, as well as the changes in the expression profile of genes
involved in lipid metabolism (Fergani et al., 2007; Gonzalez de
Aguilar et al., 2008; Thau et al., 2012). Interestingly, the pre-
dominance of oxidative metabolism goes along with deficiency in
oxidative mitochondrial chain function, in particular in the mus-
cles of ALS patients (Echaniz-Laguna et al., 2002; Dupuis et al.,
2003; Crugnola et al., 2010). Mitochondria bioenergetic functions
are impaired, as shown by Zhou and colleagues, whom described
the presence of defective mitochondria in mass near the neu-
romuscular junctions that may contribute to the progression of
muscle atrophy in ALS (Zhou et al., 2010). The origin of mito-
chondrial defect is under investigation. Several potential pathways
are proposed to explain the shift in metabolism and the alter-
ations of mitochondrial functions, and they concern the tuning
of metabolic pathways.
Mitochondrial biogenesis and functions are orchestrated in
part by peroxisome proliferator-activated receptor gamma coac-
tivator (PGC)-1 alpha (Lin et al., 2002, 2005; Handschin, 2010).
In ALS, the implication of PGC-1 alpha has been recently high-
lighted, as its expression is diminished in the muscles of patients
and SOD1 mice (Thau et al., 2012). The downregulation of PGC-
1 alpha triggersmodification of lipidmetabolism, and impacts the
use of fatty acids (Barroso et al., 2011). Interestingly, we have very
recently shown that deficiency in PGC1-alpha leads to hasten dis-
ease progression in the males of a mouse model of ALS (Eschbach
et al., 2013), strengthening the relation between lipid metabolism
alterations and disease progression, at least in SOD1 mice. When
Da Cruz and collaborators overexpressed PGC1-alpha selectively
in the muscles of SOD1 mice, they observed improved locomotor
activity and reduced muscle atrophy, but no effects on the over-
all survival of this mouse line (Da Cruz et al., 2012). Their
results suggest that improving muscle activity and reducing atro-
phy through increased PGC1-alpha could be used as a palliative
treatment in ALS. In addition, the overexpression of PGC1-alpha
selectively in the central nervous system (CNS) of SOD1 mice
restored the activity of mitochondrial complexes in the spinal
cord, supported motor functions and enhances survival by 8%
(Zhao et al., 2011). Moreover sirtuin 3, a downstream target of
PGC-1 alpha, protects neurons in vitro against SOD1 G85R toxi-
city (Song et al., 2013). General mitochondrial activity, including
mitochondrial proliferation, is impaired in ALS and represents
a promising therapeutic target for ALS as recently discussed
(Cozzolino et al., 2013; Dupuis, 2013; Pasinetti et al., 2013).
Stearoyl-Coa desaturase 1 (SCD-1) is a key enzyme for the
regulation of fatty acid metabolism, and it can impact fatty
acid oxidation taking place in mitochondria. SCD-1 introduce a
double bond in the carbon chain of saturated, to generatedmono-
unsaturated fatty acids that are more prone to be stored in fat
tissues. We have recently reported a downregulation of SCD-1 in
the muscle of SOD1 mice (Hussain et al., 2013), and in a subpop-
ulation of ALS patients (Pradat et al., 2011). The function of SCD-
1 is associated to regulation of energetic metabolism, and most
particularly the management of lipid reserves. Downregulation of
SCD-1 is known to trigger increased expression of genes involved
in the beta-oxidation of fatty acids, increased energy expendi-
ture and reduced fat storage, a metabolic phenotype exhibited by
SOD1mice (Ntambi et al., 2002; Dupuis et al., 2004).We aimed to
study the impact of a low SCD-1 activity for the motor function.
We recently described that knock-out mice for SCD-1, and non-
transgenic mice treated with a SCD-1 inhibitor, present improved
nerve regeneration after peripheral nerve injury (Hussain et al.,
2013). Moreover, the products of SCD-1, the mono-unsaturated
fatty acids, favor cytotoxic SOD-1 aggregation (Kim et al., 2005),
and the accumulation of toxic lipid species such as ceramide
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(Dobrzyn et al., 2005), suggesting that loss of SCD-1 activity
could lower cytotoxicity in ALS. Further work is needed to under-
stand the link between loss of SCD-1 activity and benefits for
the motor units, especially in ALS. Aside from its role in ener-
getic metabolism, SCD-1 is additionally required in the synthesis
of more complex lipids, including phospholipids. Alterations in
lipid metabolism will have repercussion not only on the energy
homeostasis, but also on a wide range of cellular functions,
including membrane fluidity and signaling.
A ROLE FOR LIPIDS BESIDE ENERGETIC METABOLISM
Lipids play a critical role in the structure of the central and
peripheral nervous systems in particular at the cell membrane
level. They control membrane fluidity, improve transmission of
electrical signals and stabilize synapses.
MEMBRANE FLUIDITY
Basic cellular functions depend on the composition in lipids of
plasmatic membranes. Enrichment of sphingolipids and choles-
terol, as well as content in polyunsaturated fatty acids (PUFA),
directly determines membrane fluidity and movement of mem-
brane proteins in lipid rafts (Xu et al., 2001; Lang, 2007; Lingwood
and Simons, 2010). Although the level of these lipids is altered
in ALS patients and SOD1 mice, membrane fluidity per se has
not been extensively investigated. One recent study described
loss of membrane fluidity in the SOD1 mice at disease onset
(Miana-Mena et al., 2011) presumably due to oxidative stress
and lipid peroxidation. Membrane phospholipids in the CNS are
rich in PUFA and in particular of docosahexaenoic acid (DHA).
Interestingly, the profile of fatty acids in the brain cortex and
spinal cord of ALS patients revealed an increase of DHA level
with potential consequences on membrane fluidity (Ilieva et al.,
2007). Changes in the membrane fluidity could affect wide range
of cellular functions such as ligand-receptor signal transduc-
tion and membrane trafficking (Simons and Vaz, 2004), with
consequences on cell functions and survival.
A DIRECT ROLE FOR LIPIDS IN MOTORNEURON SURVIVAL?
Back in 2002, the group of Pr. Mattson studied the lipid
metabolites present in the spinal cord of both ALS patients and
pre-symptomatic SOD1 mice, and reported higher amounts of
sphingolipids and cholesterol associated with increased lipid per-
oxidation (Cutler et al., 2002). These findings are important as
these lipid metabolites modulate vital cellular functions in the
CNS that may be involved in ALS pathophysiology. Aberrant
accumulation of ceramides is commonly seen as being toxic. It
mediates neuron death by oxidative stress and apoptosis in ani-
mal models and patients of neurodegenerative diseases (Brugg
et al., 1996; France-Lanord et al., 1997; Bras et al., 2008; Car et al.,
2012; Filippov et al., 2012). Ceramides are precursor molecules at
the crossroads of the sphingolipid metabolism and they can be
converted into sphingomyelin, ceramide-1-phosphate and gan-
gliosides. Abnormal repartition of gangliosides was described
in the CNS of ALS patients and presence of antibodies anti-
gangliosides has been described in their serum (Mizutani et al.,
2003). Gangliosides are important for axonal function and regen-
eration, and neuronal survival (Akasako et al., 2011). In the
80’s, clinicians initiated half-dozen trials in ALS with injection
of gangliosides with the aim to protect the motor units, but lead
to no benefit (Bradley, 1984; Hallett et al., 1984). These stud-
ies were however underpowered. Sphingomyelin is particularly
abundant in the nervous systems and represents another lipid
impacting motor neuron survival. Cutlers and colleagues pro-
posed that the increase of sphingomyelin in the spinal cord of ALS
patients mediates motor neuron death via oxidative stress (Cutler
et al., 2002), and in 2007, another group reported that p75-
mediatedmotor neuron death is stimulated upon sphingomyelin-
associated ROS production in an animal model of ALS (Pehar
et al., 2007).
SIGNALING MOLECULES
In addition to their role in the membrane structure, PUFA also
have intrinsic functions on cell signaling, in particular on neu-
roinflammation and regulation of energetic metabolism. First,
PUFA are known to bind to transcription factors, such as liver-
X receptor and retinoic-X receptor (Yoshikawa et al., 2002), to
stimulate the expression of genes involved in energy homeosta-
sis and dysregulation of their levels could account for the altered
metabolism in ALS.
PUFA can be also converted to active molecules. Depending
on the location of the unsaturations, PUFA present either anti-
inflammatory and neuroprotective effects, for the omega 3 fatty
acids, or pro-inflammatory for omega 6 fatty acids (Schmitz
and Ecker, 2008). For instance, eicosapentaenoic and arachi-
donic acids can be oxidized to give rise to prostanglandins or
leukotrienes, and the oxidation of DHA produces the neuropro-
tectin D1, a signaling molecule that promotes beneficial effects
on cell survival under stress (Bazan et al., 2011). Prostaglandin
E2 (PGE2) is synthetized by cyclooxygenase-2 from the arachi-
donic acid, an omega 6 fatty acid, to promote inflammation
after binding to its receptor. In ALS patients, level of PGE2 is
increased in the serum and the cerebrospinal fluid (Ilzecka, 2003).
Evidence from animal models also suggests a role for PGE2 in ALS
physiopathology. Indeed, the pharmacological inhibition of PGE2
receptor or the silencing of the gene coding for cyclooxygenase-
2 can lower neuroinflammation in SOD1 mice, preserve motor
functions and extend survival (Pompl et al., 2003; Klivenyi et al.,
2004; Liang et al., 2008).
The omega 3 fatty acids can be converted into anti-
inflammatory and neuroprotective molecules. Many reports have
shown that treatments based on omega 3 fatty acids exert benefi-
cial effects in various animalmodels of neurodegenerative disease,
such as Parkinson’s or Alzheimer’s diseases (Arsenault et al., 2011;
Ozsoy et al., 2011). In a recent study,Michael-Titus and colleagues
investigated the neuroprotective effect of eicosapentaenoic acid,
an omega 3 fatty acid precursor for DHA, in SOD1 mice.
Unexpectedly, the treatment resulted in enhancement of neuroin-
flammation, faster disease progression and hastened death for
SOD1 mice (Yip et al., 2013). One explanation proposed by the
authors is the greater susceptibility for PUFA to be peroxidized
and therefore toxic (Kanner et al., 1987). Therefore, the increase
in DHA of spinal cord from ALS patients could favor lipid per-
oxidability, and be potentially a toxic factor in ALS (Ilieva et al.,
2007).
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Taken together, all these results clearly argue for a strong
relationship between lipid metabolism and motor neuron degen-
eration. Most of the findings originate from ALS, as it is the most
studied MNDs. However, alterations of lipid metabolism are also
present in other MNDs.
LIPID ALTERATIONS IN OTHER MOTOR NEURON DISEASES
Motor neuron degeneration is present in several diseases that
complete the spectrum of MNDs with ALS. The role of lipids
in those diseases is poorly understood, although some lines of
evidence exist.
Progressive muscular atrophy (PMA) is rare subtype of ALS
characterized by loss of lower motor neurons. To our knowledge,
only one report described alterations of circulating lipids in two
patients with a PMA syndrome (Yao et al., 1983). However, these
patients suffer from other neurological disorders making difficult
to reach a conclusion.
SBMA is characterized by progressive muscle atrophy and
degeneration of lower motor neurons in the brain stem and
spinal cord. Role and regulation of lipids have not been accessed
in SBMA patients, although androgen receptors are known to
modulate lipid metabolism (Singh et al., 2006). Indeed, the anal-
ysis of the muscle transcriptome of SBMA mice revealed that
several differentially regulated genes relate to lipid metabolism,
from an energetic and a structural point of view (Mo et al.,
2010). For instance, the phospholipase A2, group VII (PLA2g7)
is downregulated in the muscles of SBMAmice. PLA2g7 degrades
phospholipids to release poly-unsaturated fatty acid and, in mus-
cle, it is involved in the differentiation of myoblasts (Xiao et al.,
2012) and reduction of adiposity (Rao et al., 2006). Ddit4l is
another example of genes deregulated in SBMAmice. Ddit4l, also
known as REDD2, is involved in muscle growth via stimulation of
the IGF1/mTOR pathway and muscle fiber switch from oxidative
to glycolytic metabolism (Pisani et al., 2005; Miyazaki and Esser,
2009; Mo et al., 2010).
SMA is a progressive, recessively inherited, neuromuscular dis-
ease. SMA is characterized by weakness and muscle atrophy due
to loss of spinal cord motor neurons. Similarly to ALS, metabolic
abnormality is part of pathophysiology of SMA. In SMA, an ini-
tial study reported normal bodymass index in amixed population
of SMA patients with severe to moderate symptoms. However, in
this cohort, the authors described a reduction in fat-free mass but
an increase in total fat mass (Sproule et al., 2009). A second study,
focusing only on the most severe form of the disease, described
a lower calorie intake than the recommended dietary allowance
in SMA patients, associated to higher fat mass (Poruk et al.,
2012). These alterations potentially participate to failure to thrive
described in SMA patients. The reason why SMA patients have
high fat mass despite low caloric intake is unclear but strengthen
the role of metabolism of lipids in the disease. Indeed, a mis-
use of lipids has been documented in SMA patients with various
symptom severities, with an impaired mitochondrial fatty acid
beta-oxidation and a loss of free circulating carnitine, arguing
for impairment of fatty acid entry into mitochondria (Tein et al.,
1995). Later, the same group of clinicians described fatty acid
abnormalities in SMA, such as high dicarboxylic acid to ketone
ratio in the plasma when fasting, or low C12:C14 fatty acid ratio,
that further decreased within disease duration. These two param-
eters are strong markers for fatty acid beta oxidation defects
(Crawford et al., 1999). The authors concluded that fatty acid
abnormality in severe SMA is primary and general defect, directly
caused by the loss of the SMN function.
Additionally, in a transgenic animal model of SMA, deficient
for the SMN gene, pups survive longer when mothers were fed
with a diet enriched in lipid content (Table 2). The treatment
also corrected motor dysfunction despite lack of effect on motor
neuron survival (Butchbach et al., 2010). Recently, a clinical trial
investigated the effect of a combined treatment of valproic acid
and L-carnitine in SMA patients, however, no to limited positive
effects have been reported in ambulatory and non-ambulatory
SMA patients (Swoboda et al., 2010; Kissel et al., 2011). However,
further work is required to assess the role of lipids in SMA and
their therapeutic potential.
PATHS TO EXPLORE
Clinical studies and basic research undoubtedly demonstrate
a particular connection between lipid metabolism and ALS
(Table 4). Contrary to that observed in other neurological dis-
eases, such as Alzheimer’s and Parkinson’s diseases, or even ageing
(Maswood et al., 2004; Patel et al., 2005), high level of lipids pos-
itively correlates to better prognosis in ALS. Preclinical data and
clinical studies clearly show that dietary lipid supplementation is
a promising strategy to treat ALS, although there is no extensive
clinical research at this level.
We are aware of only three clinical trials based on nutritional
intervention. In a recently published article, Dorst and colleagues
aimed to stop weight loss in ALS patients with high caloric diets,
either based on fats or carbohydrates. Both interventions were
able to stabilize weight loss although the effect was larger in the
high-fat diet group (Dorst et al., 2013). Another trial aims to
correct malnutrition with high fat dietary supplement in ALS
patients (NCT00983983). The second ongoing trial is a phase
III that use high ketogenic supplementation (high fat and low
carbohydrate) in ALS patients fed through a gastrostomy tube
(NCT01016522). These studies are dedicated to the prevention
of malnutrition in ALS patients, and are not designed to identify
benefit on prognosis after high fat diet. In parallel, how patients
on and off respiratory support use diverse nutritional substrates
(e.g., lipids) is under investigation (NCT00714220), as well as
the influence of lipid lowering therapy in ALS (NCT01592084).
There are two additional trials based on pharmacological mod-
ulation of energetic metabolism, using pioglitazone or olanza-
pine. Pioglitazone is an anti-diabetic drug known to manage
energetic metabolism and to lower level of circulating lipids in
patients suffering from metabolic disorders. This phase II clin-
ical trial has been stopped after interim analysis that revealed
no benefit after treatment on primary and secondary outcomes
(Dupuis et al., 2012, NCT00690118). A phase II/III using olan-
zapine is currently ongoing. Olanzapine is a neuroleptic drug
with metabolic side effects, and investigators treated ALS patients
with olanzapine, based on the weight-increasing effect of the drug
(NCT00876772). Study results have not been released yet. The
results of these trials will certainly help to determine whether
modulation of lipids, though supplementation or pharmacology,
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is a feasible and rational treatment for ALS, and potentially for
other MNDs.
As discussed in this review, the role of lipids in ALS and
MND pathophysiology goes beyond energetic metabolism, to
structure and signaling. These alterations, in particular those in
the CNS, could represent an important source of therapeutic
options in ALS. Indeed, there is a large spectrum of drugs tar-
geting sphingolipids that are well characterized in terms of safety
and bioavailability. They could be suitable for ALS patients, once
clear targets are identified. A clinical trial has been very recently
registered with the aim to test in ALS patients, the safety and tol-
erability of fingolimod, an agonist for sphingosine-1-phosphate
receptors (NCT01786174), already used in multiple sclerosis to
lower neuroinflammation in the CNS. In addition to pharma-
cological agents, dietary supplementation with neuroprotective
and anti-inflammatory fatty acids, or derivatives, is worthy of fur-
ther characterization. Altogether, alterations of lipid metabolism
in MND deserve further work that will undoubtedly lead to new
and interesting therapeutic options for patients.
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